On March 20, 2023 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, reported that its full-year 2022 financial results will be released after the markets close on Tuesday, March 28th (Press release, DiaMedica, MAR 20, 2023, View Source [SID1234629055]). DiaMedica will host a live conference call on Wednesday, March 29th at 7:00 AM Central Time to provide a business update and discuss financial results.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Conference Call details:
Date:
Wednesday, March 29, 2023
Time:
7:00 AM CDT / 8:00 AM EDT
Web access:
Dial In:
(877) 550-1858
Conference ID:
1754341
Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on our website, under investor relations – events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until April 5, 2023, by dialing (800) 645-7964 (US Toll Free) and entering the replay passcode: 2125#.